Middle Ear Administration of a Particulate Chitosan Gel in an
auditory brainstem response
cisplatin
hair cell
hearing loss
intratympanic administration
magnetic resonance imaging
particulate chitosan
sodium thiosulfate
Journal
Frontiers in cellular neuroscience
ISSN: 1662-5102
Titre abrégé: Front Cell Neurosci
Pays: Switzerland
ID NLM: 101477935
Informations de publication
Date de publication:
2019
2019
Historique:
received:
31
01
2019
accepted:
29
05
2019
entrez:
12
7
2019
pubmed:
12
7
2019
medline:
12
7
2019
Statut:
epublish
Résumé
Middle ear (intratympanic, IT) administration is a promising therapeutic method as it offers the possibility of achieving high inner ear drug concentrations with low systemic levels, thus minimizing the risk of systemic side effects and drug-drug interactions. Premature elimination through the Eustachian tube may be reduced by stabilizing drug solutions with a hydrogel, but this raises the secondary issue of conductive hearing loss. This study aimed to investigate the properties of a chitosan-based particulate hydrogel formulation when used as a drug carrier for IT administration in an Two particulate chitosan-based IT delivery systems, Thio-25 and Thio-40, were investigated in albino guinea pigs ( Both chitosan-based IT delivery systems caused ABR threshold elevations ( Particulate chitosan is a promising drug carrier for IT administration. Future studies should assess whether the physical properties of this technique allow for a smaller injection volume that would reduce conductive hearing loss.
Sections du résumé
BACKGROUND
BACKGROUND
Middle ear (intratympanic, IT) administration is a promising therapeutic method as it offers the possibility of achieving high inner ear drug concentrations with low systemic levels, thus minimizing the risk of systemic side effects and drug-drug interactions. Premature elimination through the Eustachian tube may be reduced by stabilizing drug solutions with a hydrogel, but this raises the secondary issue of conductive hearing loss.
AIM
OBJECTIVE
This study aimed to investigate the properties of a chitosan-based particulate hydrogel formulation when used as a drug carrier for IT administration in an
MATERIALS AND METHODS
METHODS
Two particulate chitosan-based IT delivery systems, Thio-25 and Thio-40, were investigated in albino guinea pigs (
RESULTS
RESULTS
Both chitosan-based IT delivery systems caused ABR threshold elevations (
CONCLUSION
CONCLUSIONS
Particulate chitosan is a promising drug carrier for IT administration. Future studies should assess whether the physical properties of this technique allow for a smaller injection volume that would reduce conductive hearing loss.
Identifiants
pubmed: 31293387
doi: 10.3389/fncel.2019.00268
pmc: PMC6603134
doi:
Types de publication
Journal Article
Langues
eng
Pagination
268Références
Hear Res. 2003 Mar;177(1-2):21-31
pubmed: 12618314
Hear Res. 2004 Jan;187(1-2):44-50
pubmed: 14698086
Hear Res. 2004 Jul;193(1-2):25-30
pubmed: 15219317
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
Exp Biol Med (Maywood). 2006 Nov;231(10):1638-45
pubmed: 17060685
Hear Res. 2007 Apr;226(1-2):157-67
pubmed: 17113254
Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6229-34
pubmed: 17400755
Laryngoscope. 2008 Apr;118(4):706-11
pubmed: 18182968
Acta Otolaryngol. 2009 Feb;129(2):132-7
pubmed: 18607994
J Otolaryngol. 1991 Jun;20(3):158-67
pubmed: 1870163
Ear Hear. 2009 Feb;30(1):81-9
pubmed: 19125030
Eur J Pharm Sci. 2010 Jan 31;39(1-3):110-5
pubmed: 19931387
Am J Pathol. 2010 Mar;176(3):1169-80
pubmed: 20110413
J Neurosci. 2010 Jul 14;30(28):9500-9
pubmed: 20631178
Cancer Chemother Pharmacol. 2011 Dec;68(6):1547-56
pubmed: 21533919
J Appl Toxicol. 2012 Apr;32(4):293-9
pubmed: 21590781
J Control Release. 2013 Mar 28;166(3):268-76
pubmed: 23313113
Laryngoscope. 2013 Dec;123(12):3172-7
pubmed: 23754209
Sci Transl Med. 2014 Jan 29;6(221):221ra15
pubmed: 24477002
Otolaryngol Head Neck Surg. 2014 Jun;150(6):983-90
pubmed: 24618499
Vaccine. 2014 Oct 14;32(45):5967-74
pubmed: 25218298
Adv Food Nutr Res. 2014;73:15-31
pubmed: 25300540
Otol Neurotol. 2015 Feb;36(2):341-7
pubmed: 25587675
Acta Otolaryngol. 2015;135(10):985-94
pubmed: 26146023
Sci Transl Med. 2015 Oct 7;7(308):308re8
pubmed: 26446958
Hear Res. 2016 Aug;338:52-63
pubmed: 26802581
Exp Toxicol Pathol. 2016 Apr;68(4):197-204
pubmed: 26850526
Hear Res. 2016 Dec;342:101-111
pubmed: 27725177
Lancet Oncol. 2017 Jan;18(1):63-74
pubmed: 27914822
Front Cell Neurosci. 2017 Sep 13;11:280
pubmed: 28955207
Front Cell Neurosci. 2017 Oct 27;11:338
pubmed: 29163050
Vet Dermatol. 2018 Apr 17;:null
pubmed: 29664150
N Engl J Med. 2018 Jun 21;378(25):2376-2385
pubmed: 29924955
Int Tinnitus J. 2018 Jun 01;22(1):40-45
pubmed: 29993216
Front Cell Neurosci. 2018 Aug 21;12:271
pubmed: 30186120
Int J Nanomedicine. 2018 Nov 14;13:7517-7531
pubmed: 30532536
J Otolaryngol Head Neck Surg. 2019 Jan 16;48(1):4
pubmed: 30651130
Polymers (Basel). 2018 Mar 05;10(3):null
pubmed: 30966302
Bioorg Chem. 2019 Jul;88:102925
pubmed: 31003078
Int J Biol Macromol. 1994 Feb;16(1):43-9
pubmed: 8180144
Hear Res. 1996 Dec 1;102(1-2):90-8
pubmed: 8951454
Laryngoscope. 1998 Nov;108(11 Pt 1):1682-5
pubmed: 9818826